Periostin is a 90‑kDa
extracellular matrix protein, which is secreted primarily from fibroblasts and is expressed in the lungs, kidneys and heart valves.
Angiotensin II (AT‑II) serves pivotal roles in the pathogenesis of several diseases with accompanying
fibrosis, including chronic
liver diseases. AT‑II induces
periostin expression by regulating transforming growth factor‑β1 (TGF‑β1)/Smad signaling during cardiac
fibrosis. The aim of the present study was to investigate the interaction between AT‑II and
periostin during
liver fibrosis development. Fischer 344 rats were fed a choline‑deficient L‑amino‑acid (
CDAA)‑defined diet for 12 weeks to simulate the development of
steatohepatitis with
liver fibrosis.
Losartan, an AT‑II type I receptor blocker, was administered to inhibit the effect of AT‑II. The
therapeutic effect of
losartan on hepatic
fibrosis development and on
periostin expression was then evaluated. Several in vitro experiments were performed to examine the mechanisms underlying the interaction between AT‑II and
periostin in activated hepatic stellate cells (Ac‑HSCs). Treatment with
losartan suppressed the development of
liver fibrosis induced by the
CDAA diet, and reduced hepatic
periostin expression. In addition,
losartan treatment suppressed hepatic Ac‑HSC expansion and hepatic TGF‑β1 expression. In vitro analysis using LX2 HSC cells indicated that AT‑II can augment TGF‑β1 and
collagen type I α1
mRNA expression via
periostin expression, suggesting that the interaction between AT‑II and
periostin may serve a role in
liver fibrosis development. In conclusion, blockade of AT‑II‑induced
periostin may suppress the progression of
liver fibrosis development.